Review



multitarget antiangiogenic agents  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals multitarget antiangiogenic agents
    Multitarget Antiangiogenic Agents, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/multitarget antiangiogenic agents/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    multitarget antiangiogenic agents - by Bioz Stars, 2026-05
    90/100 stars

    Images



    Similar Products

    antiangiogenic agent bevacizumab  (MedChemExpress)
    95
    MedChemExpress antiangiogenic agent bevacizumab
    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical <t>bevacizumab</t> (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.
    Antiangiogenic Agent Bevacizumab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antiangiogenic agent bevacizumab/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    antiangiogenic agent bevacizumab - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    antiangiogenic agents  (Firstline Biopharmaceuticals Corporation)
    90
    Firstline Biopharmaceuticals Corporation antiangiogenic agents
    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical <t>bevacizumab</t> (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.
    Antiangiogenic Agents, supplied by Firstline Biopharmaceuticals Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antiangiogenic agents/product/Firstline Biopharmaceuticals Corporation
    Average 90 stars, based on 1 article reviews
    antiangiogenic agents - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    multitarget antiangiogenic agents  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget antiangiogenic agents
    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical <t>bevacizumab</t> (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.
    Multitarget Antiangiogenic Agents, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/multitarget antiangiogenic agents/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    multitarget antiangiogenic agents - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    biomimetic antiangiogenic agent  (BioMimetic Therapeutics)
    90
    BioMimetic Therapeutics biomimetic antiangiogenic agent
    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical <t>bevacizumab</t> (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.
    Biomimetic Antiangiogenic Agent, supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/biomimetic antiangiogenic agent/product/BioMimetic Therapeutics
    Average 90 stars, based on 1 article reviews
    biomimetic antiangiogenic agent - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    antiangiogenic agents  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals antiangiogenic agents
    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical <t>bevacizumab</t> (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.
    Antiangiogenic Agents, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antiangiogenic agents/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    antiangiogenic agents - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    antiangiogenic agents  (Gilead Sciences)
    97
    Gilead Sciences antiangiogenic agents
    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical <t>bevacizumab</t> (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.
    Antiangiogenic Agents, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antiangiogenic agents/product/Gilead Sciences
    Average 97 stars, based on 1 article reviews
    antiangiogenic agents - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier
    antiangiogenic agents  (Wolters Kluwer Health)
    90
    Wolters Kluwer Health antiangiogenic agents
    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical <t>bevacizumab</t> (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.
    Antiangiogenic Agents, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antiangiogenic agents/product/Wolters Kluwer Health
    Average 90 stars, based on 1 article reviews
    antiangiogenic agents - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    antiangiogenic agents  (Genentech inc)
    90
    Genentech inc antiangiogenic agents
    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical <t>bevacizumab</t> (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.
    Antiangiogenic Agents, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antiangiogenic agents/product/Genentech inc
    Average 90 stars, based on 1 article reviews
    antiangiogenic agents - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical bevacizumab (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.

    Journal: Theranostics

    Article Title: Pattern recognition of microcirculation with super-resolution ultrasound imaging provides markers for early tumor response to anti-angiogenic therapy

    doi: 10.7150/thno.89306

    Figure Lengend Snippet: Progressive response of tumor microvascular heterogeneity to anti-angiogenic therapy. (A-B) Representative three-dimensional (3D) morphological and functional maps of tumor microvasculature from typical bevacizumab (B) and PBS-treated tumors (A) during treatment. The 3D microvasculature is shown as a 2D maximum-intensity projection. Corresponding density distribution in the pattern recognition of microcirculation (PARM)-reconstructed functional feature space is demonstrated accordingly, with 2D projection shown above the 3D density plots. The speed values were normalized for demonstration. (C, D) The longitudinal changes of PARM-derived heterogeneity parameters and pathological indicators. Differences in parameters during treatment were determined by two-way ANOVA with Bonferroni correction (* = P < 0.05, ** = P < 0.01). White scale bar: 1 mm.

    Article Snippet: The clinically used antiangiogenic agent bevacizumab (MedChemExpress, NJ, USA, #HY-P9906) was diluted in phosphate-buffered saline (PBS, pH 7.4, Hyclone, USA), and was administered every other day for 12 days ( ) via intraperitoneal injection at a dose of 10 mg/kg for animals in the treatment group.

    Techniques: Functional Assay, Derivative Assay